ASX200 Trade Table
Our ASX200 Trade Table has seen a build-up of new positions as the XJO displays positive momentum following the recent pivot low.
To access the Trade Table signals – start your free 14 day trial
S&P500 & Market Direction
Sorry, but this content is restricted to our members.
Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.
If you are having an issue with your account, then please get in touch with us.
Nasdaq Index
The NASDAQ has been helping to support the overall inflated market valuation. We are concerned that the momentum has now faltered and suggest some portfolio protection and/or inverse ETF exposure.
Intel
INTC:NAS has moved to TSMC 3nm. That ensures the company’s GPU success is not tied to its new foundry business. Intel’s U.S. government support remains critical, and the new 18A node should help generate revenue growth.
We’re yet to see a shift in momentum, and the stock remains under Algo Engine sell conditions.
Meta
META:NAS is forecast to deliver 22% revenue growth this year, with sustained growth driven by AI and digital advertising.
Meta announced its Q3 results on October 30th, reporting 20% revenue growth and 26% operating profit growth. Q4 revenue should be $45-48 billion.
Meta was added to our US Tech Disruptors portfolio in August last year, and since then, the stock has increased 120%.
LAM Research
Lam Research Corporation – Common is rated a buy with a stop loss at $70.40
GE Healthcare
GE HealthCare Technologies Inc. – Common is rated a buy at $83
Medtronic
Medtronic plc. Ordinary is rated a buy $86
JD.COM
JD:NAS is rated a buy at $37
Level 29 Chifley Tower
2 Chifley Square
Sydney, NSW 2000
1300 614 002
Investor Signals Pty Ltd
ABN 44 143 555 453
Send our ASX Research to your Inbox
Or start a free thirty day trial for our full service, which includes our ASX Research.